Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: Its clinicopathological significance'

Modern Pathology

Volumn 26, Issue 4, 2013, Pages 610-611

  Lee, Hee Jin ^a   Park, So Yeon ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; GENE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; LETTER; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS;

EID: 84876498857     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.38     Document Type: Letter

References (7)

1. Seol H, Lee HJ, Choi Y, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012; 25:938-948.
2. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133: 611-612.
3. Layfield LJ, Schmidt RL. HER2/neu gene amplification heterogeneity: the significance of cells with a 3: 1 HER2/CEP17 ratio. Appl Immunohistochem Mol Morphol 2012;20:543-549.
4. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 2011;136:864-871.
5. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
6. Bartlett JM, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011;29:1531-1538.
7. Dowsett M, Procter M, McCaskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-2969.